Clinical Subtype-Derived p53 Gene Signature Is Predictive of Prognosis and Response to Chemotherapy in ER-Positive but Not in ER-Negative Breast Cancers.
Pusztai L, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Symmans W, Andre F, de The H, Coutant C, Coutant C. Clinical Subtype-Derived p53 Gene Signature Is Predictive of Prognosis and Response to Chemotherapy in ER-Positive but Not in ER-Negative Breast Cancers. Cancer Research 2009, 69: 6122-6122. DOI: 10.1158/0008-5472.sabcs-09-6122.Peer-Reviewed Original ResearchDistant metastasis-free survivalP53 signatureBreast cancerER- cancersPredictive valueWorse distant metastasis-free survivalSystemic adjuvant therapyER- breast cancerMetastasis-free survivalNegative breast cancerDifferent molecular subtypesP53 functional statusP53 gene mutationsGene expression-based predictorsP53 mutation statusAdjuvant tamoxifenAdjuvant therapyFree survivalBackgroundBreast cancerFunctional statusMolecular subtypesIndependent cohortNeoplastic diseaseChemotherapy sensitivityMutation status